FDA cancels vaccine advisory meeting for choosing flu strains for next season’s shots

FDA cancels vaccine advisory meeting for choosing flu strains for next season’s shots


FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. 

Jason Reed | Reuters

A crucial March meeting of vaccine advisors to the Food and Drug Administration has been canceled without explanation, a member of the advisory panel told CNBC on Wednesday. 

The meeting of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, is held every March to select flu strains for shots released in the upcoming fall and winter. 

But Dr. Paul Offit, a member of that panel, told CNBC that he received an email at 4:18 p.m. ET on Wednesday saying that the upcoming March 13 meeting is canceled. He said there was no indication of whether it will be rescheduled.

“Who canceled this meeting? Why did they cancel the meeting? Will manufacturers now turn to the World Health Organization to determine strains for this year’s influenza vaccines?” Offit told CNBC. 

The Department of Health and Human Services did not immediately respond to a request for comment.

The canceled meeting comes as Robert F. Kennedy Jr., who now leads HHS, makes early moves that could affect vaccination uptake and policy in the U.S. Kennedy has a lengthy track record of being a vaccine skeptic. 

It also comes amid a particularly brutal flu season in the U.S. CDC data shows the flu has caused up to an estimated 910,000 hospitalizations since October, which puts the season on track to be the most severe in at least a decade.

Earlier this month, a separate meeting of advisors who help the Centers for Disease Control and Prevention make recommendations for vaccines was postponed to “accommodate public comment in advance of the meeting,” several news outlets reported. It is also unclear if that meeting will be rescheduled. 

Kennedy also said last week that he will review the childhood vaccine schedule despite earlier pledges not to do so. He promised that a new “Make America Healthy Again” commission would investigate vaccines, pesticides and antidepressants to see if they have contributed to a rise of chronic illness in the U.S.

Meanwhile, the Trump administration is weighing pulling funding for Moderna’s bird flu vaccine, Bloomberg reported on Wednesday.

The country is grappling with a record-breaking bird flu outbreak that’s impacted dozens of cattle herds along with poultry flocks, which has sent egg prices skyrocketing. Its rapid spread in animals has raised concerns about broader spread to humans.”



Source

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Health

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]

Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
Health

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 

Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]

Read More